This segment focuses on the commercialization and marketing of Supernus's approved products for central nervous system (CNS) disorders. Key products include Trokendi XR and Oxtellar XR for epilepsy and migraine, APOKYN and XADAGO for Parkinson's Disease, and MYOBLOC for cervical dystonia and sialorrhea. The segment's activities involve sales, marketing, and distribution through pharmaceutical wholesalers, specialty pharmacies, and distributors. Research and development efforts support lifecycle management of existing products and explore new indications. The segment's success is measured by revenue growth, market share, and patient access. Competitive advantages include a focus on specialty pharmaceuticals and a dedicated sales force. Future opportunities include expanding the product portfolio and geographic reach. Regulatory aspects involve adherence to FDA guidelines and other relevant regulations. The segment aims to improve the lives of patients suffering from neurological and psychiatric conditions by providing effective and accessible treatments.

This segment encompasses Supernus's research and development activities, focusing on the discovery and development of novel treatments for CNS disorders. The R&D pipeline includes product candidates in various stages of clinical trials, such as SPN-812 for ADHD, SPN-830 for Parkinson's Disease, SPN-817 for severe epilepsy, and SPN-820 for treatment-resistant depression. The company utilizes proprietary technologies to develop these novel treatments. Research activities include preclinical studies, clinical trials, and regulatory submissions. The segment's success is measured by the advancement of product candidates through clinical trials and regulatory approvals. The company's R&D efforts are focused on addressing unmet medical needs in neurology and psychiatry. Future opportunities include expanding the pipeline with new product candidates and exploring strategic collaborations. Regulatory aspects involve adherence to FDA guidelines and other relevant regulations. The segment aims to bring innovative treatments to market to improve patient outcomes.